Simply Sleep

New OTC sleep aid "from the makers of Tylenol PM" contains 25 mg diphenhydramine per caplet, the same ingredient and dosage level as in Tylenol PM but without the 500 mg acetaminophen. TV ads for the product say: "While some folks couldn't sleep...", showing a restless man in a bathrobe in front of a TV, presumably in the wee hours of the morning. The shot then shifts to the house next door where a woman is sleeping comfortably. The ad continues:"...you were peacefully sleeping, thanks to new Simply Sleep from the makers of Tylenol PM. It's non-habit forming and eases you into a restful night's sleep. New Simply Sleep." The ad includes a product shot of Simply Sleep's night blue box with a half moon design and corner banner "New." The phrase "from the makers of Tylenol PM" is similar in context to that used by the Clear Passage nasal strips from the makers of Afrin (Schering-Plough) ("The Tan Sheet" July 20, 1998, p. 2). McNeil Consumer Healthcare began shipping Simply Sleep in February. The sleep aid comes in two SKUs, a 24-count for $3.99-$4.29 suggested retail price and a 48-count for $6.19-$6.99

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Last Minute Course Shifts, Focus On Unknowns: What Sponsors Should Learn From Prasad’s Interventions

 

The once and current CBER director’s justification for his COVID-19 decision stands as a warning of the uncertainty sponsors, particularly those in the vaccine space, may now face at FDA.

Novaxovid And mNexspike Reviewers

 

Pink Sheet Drug Review Profile feature listing FDA staff who conducted the reviews of Novavax and Moderna's post-pandemic COVID-19 vaccines

GLP-1s In Crosshairs As Employers Worry About Health Costs – And Their Own Reliance On Rebates

 
• By 

Business Group on Health annual employer survey highlights fast-growing Rx costs, led by the GLP-1 drugs, and payer strategies for controlling them. Policy prescriptions are unclear, though, since employers are loath to leave PBMs and nervous about pending changes to Medicare and Medicaid.